Analyst Jason Gerberry of Bank of America Securities maintained a Buy rating on Liquidia Technologies, retaining the price target of $37.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason Gerberry has given his Buy rating due to a combination of factors related to Liquidia Technologies’ promising developments in their inhaled treprostinil assets. The company has received positive feedback from key opinion leaders regarding the launch of Yutrepia, particularly for its early use in treating PH-ILD, which suggests a favorable market reception. Additionally, the recent data from the ASCENT trial indicates that Yutrepia demonstrates durable efficacy and tolerability, with significant improvements in patients’ six-minute walk distance and no discontinuations due to cough, a common concern for physicians.
Furthermore, the development of L606, another inhaled treprostinil candidate, shows potential for revenue diversification and addressing more severe patient populations. The L606 formulation offers rapid delivery and enhanced tolerability, with promising open-label data supporting its efficacy. The planned pivotal study for L606, which aims to support approval for both PH-ILD and PAH, further strengthens the company’s growth prospects. These factors, combined with a price objective of $37, underpin Gerberry’s Buy rating for Liquidia Technologies.
In another report released on October 24, LifeSci Capital also maintained a Buy rating on the stock with a $54.00 price target.
Based on the recent corporate insider activity of 80 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LQDA in relation to earlier this year.